Literature DB >> 10900826

Development of a differential multiplex PCR assay for equine herpesvirus 1 and 4 as a diagnostic tool.

R Carvalho1, L M Passos, A S Martins.   

Abstract

In this study, a multiplex polymerase chain reaction (PCR) procedure was developed for differentiation of strains and field isolates of equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4). Specific oli-gonucleotide primers were combined to amplify the thymidine kinase (TK) gene region of EHV-1 and EHV-4, which would yield fragments of different lengths for each virus in the same amplification reaction. The specificity of the largest PCR amplicon for EHV-4 was confirmed by restriction digestion with HindIII. The multiplex PCR proved to be a fast and sensitive method for typing EHV-1 and EHV-4 isolates and for detection and differentiation of both viruses in field samples in which infectious virus is no longer available. The sensitivity was improved by combining cycling optimization and visualization of PCR products in ethidium bromide and silver-stained acrylamide gels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10900826     DOI: 10.1046/j.1439-0450.2000.00361.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  2 in total

1.  New real-time PCR assay using allelic discrimination for detection and differentiation of equine herpesvirus-1 strains with A2254 and G2254 polymorphisms.

Authors:  Kathryn L Smith; Yanqiu Li; Patrick Breheny; R Frank Cook; Pamela J Henney; Stephen Sells; Stéphane Pronost; Zhengchun Lu; Beate M Crossley; Peter J Timoney; Udeni B R Balasuriya
Journal:  J Clin Microbiol       Date:  2012-04-04       Impact factor: 5.948

2.  Molecular Detection of Equine Herpesvirus Types 1 and 4 Infection in Healthy Horses in Isfahan Central and Shahrekord Southwest Regions, Iran.

Authors:  Taghi Taktaz Hafshejani; Shahin Nekoei; Behnam Vazirian; Abbas Doosti; Faham Khamesipour; Madubuike Umunna Anyanwu
Journal:  Biomed Res Int       Date:  2015-09-01       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.